Proposed guidelines for the clinical evaluation of interleukin-1 inhibitors in the treatment of rheumatoid arthritis.
Since the effects of interleukin-1 might contribute to the lesions observed in rheumatoid arthritis. a compound which inhibits this cytokine should be an important addition to the therapeutic agents available for use in this disease. Clinical evaluation of such a compound must answer the following questions: Is the proposed drug "quick" or "slow" acting on the clinical and/or biological symptoms of inflammation? Is the proposed drug able to prevent and/or to stop the cartilage damage in rheumatoid arthritis? We propose some methodological guidelines for clinical trials designed to assess these compounds.